羟苯氨酮对戊巴比妥钠致心力衰竭的治疗作用

目的：研究强心扩血管新药羟苯氨酮(oxyphenamone) 对心力衰竭的治疗作用。 方法：用多导生理仪与电磁流量计测定戊巴比妥钠致心力衰竭豚鼠、 猫与狗的心脏血流动力学参数。 结果：iv 羟苯氨酮1～8 mg.kg^-1, 剂量依赖性地增加心肌收缩力、 左室收缩压、 心输出量、 心脏作功及冠状动脉血流量, 其作用强度与磷酸二酯酶抑制剂(PDEI)氨力农(amrinone) 相似。 而PDEI增加心率, 易致心律失常, 并继续降低血压; 羟苯氨酮则减慢心率, 使降低的血压上升。 结论：羟苯氨酮能明显改善心衰动物的心脏功能,其作用优于PDEI, 有可能发展成为治疗心力衰竭的新药。

THERAPEUTIC EFFECT OF A NOVEL INODILATOR OXYPHENAMONE ON EXPERIMENTAL HEART FAILURE INDUCED BY SODIUM PENTOBARBITAL

AIM: To study the therapeutic effect of oxyphenamone on heart failure. METHODS: An acute heart failure model was established by giving sodium pentobarbital iv at the dosage of 30～60 mg.kg-1 in guinea pigs, cats and dogs. RESULTS: Intravenous injection of oxyphenamone(1～8 mg.kg^-1) dose-dependently increased myocardial contractile force, left ventricular systolic pressure, ±dP/dt_max, cardiac output, left ventricular work and the blood flow of the coronary and femoral arteries. The cardiotonic effect of oxyphenamone was similar to that of phosphodiesterase inhibitors(PDEI) amrinone and milrinone. The differences between these two agents include that oxyphenamone increases mean arterial pressure(MAP) and decreases heart rate(HR) in animals with heart failure, but PDEI induces inverse effects on MAP and HR and is prone to produce arrhythmia. CONCLUSION: The results suggest that oxyphenamone is more beneficial for the treatment of heart failure.